<DOC>
	<DOCNO>NCT00048555</DOCNO>
	<brief_summary>To determine side effect clinical effect , , administration investigational product , IDEC-114 combination Rituxan速 [ Rituxan速 single agent approve United States Food Drug Administration ( FDA ) treat patient relapse refractory follicular NHL ] , patient population .</brief_summary>
	<brief_title>Safety Efficacy IDEC-114 Combination With Rituxan Treatment Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Signed IRBapproved informed consent Greater equal 18 year age Proof follicular lymphoma Progressive disease require treatment least 1 prior standard therapy Acceptable hematologic status , liver function , renal function Patients reproductive potential must agree follow accepted birth control method treatment 3 month completion treatment No response prior Rituxan速 Rituxan速containing regimen Presence CLL CNS lymphoma Known history HIV infection AIDS Prior diagnosis aggressive NHL mantlecell lymphoma Serious nonmalignant disease Pregnant currently breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>